Mid-Day Market Update: Crude Oil Rises 1%; Sage Therapeutics Shares Slide
Midway through trading Tuesday, the Dow traded down 0.45% to 34,238.18 while the NASDAQ fell 0.53% to 14,099.27. The S&P also fell, dropping 0.25% to 4,244.45.
34 Stocks Moving In Tuesday’s Mid-Day Session
Gainers
HMG/Courtland Properties, Inc. (NYSE: HMG) shares surged 133% to $27.80.
Mid-Morning Market Update: Markets Open Lower; US Retail Sales Drop 1.3% In May
Following the market opening Tuesday, the Dow traded down 0.34% to 34,275.92 while the NASDAQ fell 0.09% to 14,161.73. The S&P also fell, dropping 0.10% to 4,250.89.
Why Sage Therapeutics (SAGE) Stock Is Falling Despite Meeting Primary Endpoint In Major Depressive Disorder Trial With Zuranolone
Looking to make a comeback after a big Phase 3 flop, Sage Therapeutics Inc (NASDAQ:SAGE) revealed data from another Phase 3…
The Daily Biotech Pulse: AstraZeneca, Biogen Face Clinical Trial Disappointments, Novavax Studies Coronavirus-Flu Combo Vaccine, Decision Day For Takeda
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 14)
Sage Therapeutics – Biogen’s Zuranolone Tops Placebo In Reducing Depressive Symptoms
Sage Therapeutics Inc (NASDAQ:SAGE) and Biogen Inc (NASDAQ: BIIB) have announced data from WATERFALL Phase 3 study evaluating zuranolone (SAGE-217/BIIB125) in patients with Major…
Sage Therapeutics And Biogen Announce Pivotal Phase 3 Results For Zuranolone In Major Depressive Disorder; Study Met Primary Endpoint
At the Day 15 primary endpoint, zuranolone 50 mg showed a statistically significant and clinically meaningful reduction in depressive symptoms as measured by HAMD-17 (p=0.0141) compared to placebo
Rapid onset of